Core Insights - Fuhong Hanlin (2696.HK) has received official approval from the China Securities Regulatory Commission for its H-share full circulation filing, enhancing liquidity and governance for overseas capital access [1] - The company presented its Globalization 2.0 strategy and clinical milestone plans for core products at the 44th J.P. Morgan Healthcare Conference, aiming to launch over 20 products globally by 2030, with more than 15 expected in the U.S. and Europe [1] - Fuhong Hanlin has 10 products approved in over 60 markets, benefiting more than 950,000 patients, with ongoing expansion in overseas markets [2] H-share Full Circulation - The filing for 183 million non-listed shares for H-share full circulation has been completed, valid for 12 months, which will further enhance the company's share liquidity and governance [1] - The stock price showed strong performance, closing at HKD 68.25 on January 16, up 1.26%, with a total market capitalization of HKD 37.094 billion [1] Clinical and Product Development - The year 2026 is critical for Fuhong Hanlin's innovation pipeline and commercialization, with clear clinical and registration milestone plans for core products [2] - The anti-PD-1 monoclonal antibody Hanshuo® has been approved in over 40 markets globally, with plans to pursue gastric cancer perioperative indications in China and new indications in the U.S. and Europe [2] - The potential best-in-class PD-L1 ADC HLX43 will initiate three global key clinical studies and two proof-of-concept studies, with promising clinical data to be presented at major academic conferences [2] Global Operations and Commercialization - Fuhong Hanlin has established a solid global operational foundation, with 164 IND approvals and 66 NDA approvals, including 4 BLA approvals from the U.S. FDA [3] - The company has completed over 1,150 GMP production batches, with production facilities certified by multiple countries, ensuring stable supply for global markets [3] - The company aims to leverage stable cash flow from biosimilars to fund innovative R&D, supported by over 20 overseas partners to strengthen its global commercialization network [3]
复宏汉霖H股全流通备案尘埃落定，1.83亿股解锁激活海外资本对接潜力